English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Mallinckrodt Plc
Press release submission
| Sep 24, 2019
MALLINCKRODT: Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
Trending
+
Pharmaceuticals
Patient Daily
| Sep 23, 2025
Wall Street Journal editorial board alleges hospitals misuse 340B program
+
Pharmaceuticals
Patient Daily
| Sep 22, 2025
Nurses United for Healthcare Integrity says hospitals abuse 340B drug pricing program
Patient Daily
| Sep 19, 2025
ENT specialist on ongoing chronic sinus cases: ‘Some of it could be incomplete surgery’
+
Pharmaceuticals
Patient Daily
| Sep 22, 2025
Staff Attorney of Legal Aid Society on 340B: 'Hospitals are exploiting the 340B program'
